![]() |
市场调查报告书
商品编码
1492648
巨细胞病毒检测市场:依测试类型、样本类型、使用者群体、最终用途 – 2024-2030 年全球预测Cytomegalovirus Tests Market by Test Type (Antigenemia Tests, Culture Tests, Molecular Tests), Sample Type (Blood Samples, Urine Samples), User Group, End Use - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
巨细胞病毒检测市场规模预计2023年为6.4128亿美元,2024年将达到6.8078亿美元,预计2030年将达到10.2506亿美元,复合年增长率为6.93%。
巨细胞病毒(CMV) 检测是一种检测个体体内是否有巨细胞病毒的医学检测。巨细胞病毒是疱疹病毒科中常见的病毒,可以感染所有年龄层的人。健康人即使被感染通常也不会表现出任何症状,甚至可能没有意识到自己被感染,但鉅细胞病毒对于免疫力较弱的人来说可能很严重,对于出生前感染的新生儿可能会造成严重的健康风险。社会和临床对 CMV 影响的认识不断提高,尤其是对孕妇和免疫力缺乏患者的影响,正在推动对 CMV 检测的需求。此外,随着全球器官移植数量的增加,对准确 CMV 检测以确保移植安全和成功的需求也随之增加。然而,高成本和获得先进测试设施的机会有限可能会阻碍市场成长,特别是在新兴市场。此外,各国复杂的监管环境和不同的报销政策可能会成为采用先进 CMV 测试技术的障碍。此外,分子诊断的创新以及更快、更准确的测试方法的开拓也促进了市场的成长。利用次世代定序仪和基于 CRISPR 的技术进行 CMV 检测有可能提高灵敏度、特异性和成本效益。
主要市场统计 | |
---|---|
基准年[2023] | 64128万美元 |
预计年份 [2024] | 68078万美元 |
预测年份 [2030] | 1,025,060,000 美元 |
复合年增长率(%) | 6.93% |
区域洞察
美洲,特别是美国和加拿大,构成了巨细胞病毒(CMV)检测的重要市场。医疗基础设施的改善、医疗成本的上升以及人们对鉅细胞病毒感染疾病早期诊断和治疗重要性的认识不断提高,正在促进这些国家的市场成长。该地区消费者的需求是由对高标准医疗保健实践和先进诊断解决方案的需求所驱动的。政府和私营部门支持的持续研究和开发工作旨在提高 CMV 测试的准确性和可及性。欧盟 (EU) CMV 检测市场的特点是严格的监管标准以及病患照护和安全的重要原则。欧盟国家受益于完善的医疗保健系统和公民的高度健康意识。欧盟境内的消费者需要安全、经过验证且具成本效益的测试选项。中东拥有阿联酋和沙乌地阿拉伯等富裕国家,医疗保健产业不断发展,对医疗保健基础设施和服务的投资不断增加。相反,非洲面临医疗设施有限和缺乏意识等挑战。由于医疗支出增加、经济成长和庞大的患者数量,亚太地区正迅速崛起为重要的 CMV 检测市场。中国和印度人口众多,对负担得起的医疗保健解决方案有很高的需求,包括鉅细胞病毒等感染疾病的诊断测试。日本以其先进的医疗保健系统和技术创新而闻名,表现出对高品质、精确诊断的偏好。这些国家的研究和开发倡议专注于创建满足当地需求的具有成本效益和高效的诊断解决方案。
FPNV定位矩阵
FPNV 定位矩阵对于评估供应商在巨细胞病毒测试市场的定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对巨细胞病毒检测市场中供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外,该分析还提供了对该行业竞争性质的宝贵见解,包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对巨细胞病毒检测市场当前地位的全面评估使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[184 Pages Report] The Cytomegalovirus Tests Market size was estimated at USD 641.28 million in 2023 and expected to reach USD 680.78 million in 2024, at a CAGR 6.93% to reach USD 1,025.06 million by 2030.
Cytomegalovirus (CMV) tests are medical examinations used to detect the presence of the cytomegalovirus in an individual's body. The cytomegalovirus is a common virus that belongs to the herpesvirus family and can infect people of all ages. While healthy individuals often show no symptoms upon infection and may not be aware they have been infected, CMV can pose significant health risks to people with weakened immune systems and to newborns if they are infected before birth. Growing public and clinical awareness regarding the implications of CMV, especially in pregnant women and immunocompromised patients, drives the demand for CMV testing. Additionally, as the number of organ transplants increases globally, the need for precise CMV testing escalates to ensure safe and successful transplant outcomes. However, high costs and limited access to sophisticated testing facilities can impede market growth, particularly in developing regions. Moreover, complex regulatory landscapes and varying reimbursement policies across countries can create hurdles in the adoption of advanced CMV testing technologies. Furthermore, innovations in molecular diagnostics and the development of faster, more accurate testing methods contribute to market growth. Leveraging next-generation sequencing and CRISPR-based technologies for CMV detection offers the potential to improve sensitivity, specificity, and cost-effectiveness.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 641.28 million |
Estimated Year [2024] | USD 680.78 million |
Forecast Year [2030] | USD 1,025.06 million |
CAGR (%) | 6.93% |
Regional Insights
The Americas, particularly the United States and Canada, represent a significant market for cytomegalovirus (CMV) tests. Enhanced healthcare infrastructure, high healthcare spending, and an increasing awareness of the significance of early diagnosis and treatment of CMV infections contribute to the market's growth in these countries. The consumer need in the region is driven by a high standard of healthcare practices and a demand for advanced diagnostic solutions. Ongoing research and development activities, supported by both government and private sectors, aim to improve the accuracy and accessibility of CMV testing. In the European Union, the market for CMV tests is characterized by stringent regulatory standards and a vital principle on patient care and safety. EU countries benefit from a well-established healthcare system and high health awareness among the population. The consumer need within the EU is for safe, validated, and cost-effective testing options. The Middle East, with its wealthier nations like the UAE and Saudi Arabia, is witnessing a growing healthcare sector with increasing investments in healthcare infrastructure and services. Conversely, Africa faces challenges such as restricted access to healthcare facilities and an insufficiency of awareness. The APAC region is rapidly emerging as a significant CMV test market driven by increasing healthcare expenditure, economic growth, and a huge patient population. China and India, with their vast populations, have a high demand for affordable healthcare solutions, including diagnostic tests for infectious diseases such as CMV. Japan, known for its advanced healthcare system and technological innovation, demonstrates a preference for high-quality and precision diagnostics. Research and development initiatives in these countries are focused on creating cost-effective and efficient diagnostic solutions to meet local needs.
Market Insights
The market dynamics represent an ever-changing landscape of the Cytomegalovirus Tests Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cytomegalovirus Tests Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cytomegalovirus Tests Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
FDA Approves Expanded Use of PREVYMIS by Merck to Prevent CMV in High-Risk Kidney Transplant Recipients
The U.S. Food and Drug Administration (FDA) has recently approved a new application for Merck's antiviral drug, Prevymis (letermovir), to include its use in preventing cytomegalovirus (CMV) disease among adult recipients of kidney transplants with high-risk. Prevymis aims to significantly reduce the risk of viral infection and associated complications by preventing the activation of the virus in patients with weakened immune systems post-transplant. This decision by the FDA was supported by robust clinical trials that demonstrated the drug's effectiveness and safety in this new patient demographic, paving the way for its broader use in transplant medicine. [Published On: 2023-06-06]
DiaSorin's Breakthrough in Congenital CMV Detection
DiaSorin, an Italian diagnostic firm, announced its achievement in gaining 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its innovative Simplexa Congenital CMV Direct kit. This cutting-edge diagnostic tool marks a significant milestone as the first FDA-approved test to detect cytomegalovirus (CMV) DNA in both saliva and urine samples of newborns aged 21 days or younger. Integrating this test into the Liaison MDx instrument facilitates swift and accurate diagnoses of congenital CMV, enabling timely interventions and treatments. [Published On: 2022-11-09]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cytomegalovirus Tests Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Cytomegalovirus Tests Market, highlighting leading vendors and their innovative profiles. These include Abbexa Ltd., Abbott Laboratories, Accubiotech Co., Ltd, AdvaCare Pharma USA, Agilent Technologies, Inc., Atlas Medical GmbH, Bio-Rad Laboratories, Inc., Biogenix Inc. Pvt. Ltd., CLONIT srl, Creative Diagnostics, CTK Biotech Inc. by SSI Diagnostica A/S, Diasorin S.p.A., Elabscience Bionovation Inc., F. Hoffmann-La Roche Ltd., Hangzhou Realy Tech Co., Ltd., Intec Products, Inc., IQ Products B.V., Jiangsu Macro & Micro-Test Med-Tech Co., Ltd., Meridian Bioscience, Inc. by SD Biosensor, and Thermo Fisher Scientific Inc.
Market Segmentation & Coverage